First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort

被引：1

作者：

Yang, J. C-H. ^{[1
,2
]}

Kobayashi, K. ^{[3
]}

Chewaskulyong, B. ^{[4
]}

Tran, T. V. ^{[5
]}

Biswas, B. ^{[6
]}

Lee, K. H. ^{[7
]}

Feng, P-H. ^{[8
]}

Pham, X. D. ^{[9
]}

Yao, Y. ^{[10
]}

Kuyama, S. ^{[11
]}

Bing, J. Y. Tan Chun ^{[12
]}

Bhise, R. ^{[13
,14
]}

Ahn, M-J. ^{[15
]}

Sriuranpong, V. ^{[16
,17
]}

Li, R. K. ^{[18
]}

Monterroso, E. Armenteros ^{[19
]}

Barrett, K. ^{[20
]}

Albayaty, M. ^{[21
]}

Cheng, Y. ^{[22
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan

[2] Natl Taiwan Univ, Grad Inst Oncol, Taipei, Taiwan

[3] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan

[4] Chiang Mai Univ, Dept Med, Chiang Mai, Muang, Thailand

[5] Univ Med Ctr, Dept Chemotherapy, Ho Chi Minh City, Vietnam

[6] Tata Med Ctr, Dept Med Oncol, Kolkata, India

[7] Chungbuk Natl Univ, Dept Internal Med, Cheongju, South Korea

[8] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Taipei, Taiwan

[9] HCMC Oncol Hosp, Dept Med Oncol, Ho Chi Minh City, Vietnam

[10] Xi An Jiao Tong Univ, Affiliated Hosp 1, Med Oncol, Xian, Peoples R China

[11] Natl Hosp Org Iwakuni Clin Ctr, Dept Resp Med, Iwakuni, Japan

[12] Cebu Doctors Univ Hosp, Dept Internal Med, Cebu, Philippines

[13] JN Med Coll, Dept Med Oncol, Belagavi, India

[14] KLES Dr Prabhakar Kore Hosp & MRC, Belagavi, India

[15] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[16] Chulalongkorn Univ, Fac Med, Div Med Oncol, Bangkok, Thailand

[17] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[18] St Lukes Med Ctr, Inst Canc, Quezon City, Philippines

[19] AstraZeneca, Oncol R&D, Late Stage Dev, Barcelona, Spain

[20] AstraZeneca, Oncol R&D, Late Stage Dev, Biometr, Cambridge, England

[21] AstraZeneca, Oncol R&D, Late Stage Dev, Cambridge, England

[22] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

630MO

引用

页码：S1635 / S1636

页数：3

共 50 条

[1] First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Cheng, Y.
Yu, Y.
Fan, Y.
Jiang, L.
Wu, L.
Hu, J.
Wang, J.
Yao, W.
Han, Z.
Yao, Y.
Fang, J.
Sun, M.
Wang, Q.
Pan, Y.
Wu, R.
Liu, J.
Liu, Y.
Kulkarni, D.
Huang, X.
Janne, P. A.
ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1689
[2] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Planchard, D.
Janne, P. A.
Cheng, Y.
Lee, C. K.
Laktionov, K.
Yang, T-Y.
Yu, Y.
Kato, T.
Jiang, L.
Chewaskulyong, B.
Geater, S. Lucien
Maurel, J-M.
Rojas, C.
Havel, L.
Shepherd, F. A.
Tanaka, K.
Ghiorghiu, D.
Monterroso, E. Armenteros
Huang, X.
Yang, J. C-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1668 - S1668
[3] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Planchard, D.
Janne, P. A.
Cheng, Y.
Lee, C. K.
Laktionov, K.
Yang, T. Y.
Yu, Y.
Kato, T.
Jiang, L.
Chewaskulyong, B.
Geater, S. Lucien
Maurel, J. M.
Rojas, C.
Havel, L.
Shepherd, F. A.
Tanaka, K.
Ghiorghiu, D.
Monterroso, E. Armenteros
Huang, X.
Yang, J. C. H.
ANNALS OF ONCOLOGY, 2023, 34 : S1311 - S1312
[4] FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
Janne, Pasi A.
Kobayashi, Kunihiko
Robichaux, Jacqulyne
Lee, Chee Khoon
Sugawara, Shunichi
Yang, Tsung-Ying
Kim, Tae Min
Yanagitani, Noriko
Kim, Sang-We
Markovets, Aleksandra
Bhetariya, Preetida
Poole, Lynne
Ghiorghiu, Dana
Hartmaier, Ryan
Yang, James Chih-Hsin
Planchard, David
CANCER RESEARCH, 2024, 84 (07)
[5] First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Planchard, D.
Poltoratskiy, A.
Kim, S-W.
Kim, T. M.
Yanagitani, N.
Kagamu, H.
Feng, P-H.
Hughes, B.
Yang, T-Y.
Yang, J. C-H.
Lee, C. K.
Karaseva, N.
Mitchell, P.
Tambo, Y.
Monterroso, E. Armenteros
Todd, A.
Sahasrabudhe, A.
Janne, P. A.
Kobayashi, K.
ANNALS OF ONCOLOGY, 2023, 34 : S1692 - S1693
[6] Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2
Lee, C. K.
Robichaux, J. P.
Janne, P. A.
Kim, S-W.
Kim, T. M.
Kobayashi, K.
Planchard, D.
Sugawara, S.
Yanagitani, N.
Yang, T-Y.
Markovets, A.
Bhetaryia, P.
Poole, L.
Rukazenkov, Y.
Hartmaier, R. J.
Yang, J. C-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1669 - S1670
[7] Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 3 - 4
[8] Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
Janne, P.
Planchard, D.
Cheng, Y.
Yang, J. C. -H.
Yanagitani, N.
Kim, S. -W.
Sugawara, S.
Yu, Y.
Fan, Y.
Geater, S. L.
Laktionov, K.
Lee, C. K.
Valdivieso, N.
Ahmed, S.
Maurel, J. -M.
Andrasina, I.
Goldman, J.
Ghiorghiu, D.
Kulkarni, D.
Huang, X.
Kobayashi, K.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S36 - S37
[9] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
Jeong, Byeong-Ho
Um, Sang-Won
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
[10] Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
Rotow, Julia K.
Costa, Daniel Botelho
Paweletz, Cloud P.
Awad, Mark M.
Marcoux, Paul
Rangachari, Deepa
Barbie, David Allen
Sands, Jacob
Cheng, Michael L.
Johnson, Bruce E.
Oxnard, Geoffrey R.
Jackman, David Michael
Kwiatkowski, David J.
Kehl, Kenneth L.
Izdebski, Monika D.
Lau, Christie J.
Vasquez, Kevin A.
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →